MOUNTAIN VIEW, Calif., Feb. 9 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today provided additional details on its relationship with Servier, a leading independent French pharmaceutical company. As announced during Pharsight’s fiscal second quarter, Servier recently became a customer for the Pharsight(R) Knowledgebase Server(TM) and is upgrading related Pharsight modeling software. The license agreement with Servier is the latest PKS agreement Pharsight has entered into with leading pharmaceutical companies in Europe and the United States.
The Pharsight Knowledgebase Server (PKS(TM)) is a high-productivity, regulatory-compliant enterprise data management system. PKS enables pharmaceutical and biopharmaceutical companies to better manage and control preclinical and clinical kinetic and dynamic data and analyses. Companies use PKS to build pharmacokinetic/pharmacodynamic data management architecture compliant with the U.S. Food and Drug Administration’s (FDA) regulation 21 CFR Part 11, which has set new standards for computer system validation and usage. The PKS software is designed to complement Pharsight’s modeling and simulation technology for computer-based drug-disease modeling and clinical trial simulation. PKS supports analysis in leading tools such as WinNonlin(R), NONMEM(R), and SAS(R).
“Pharsight’s PKS will support Servier’s continuing investment in R&D,” said Dr. Patrick Genissel, Director, PK and Metabolism, Servier. “PKS will be a critical component of our information infrastructure, not only for increasing R&D productivity, but for facilitating regulatory compliance.”
“The addition of Servier further illustrates the penetration of Pharsight’s enterprise data management solutions in the global pharmaceutical industry,” said Shawn O’Connor, Pharsight’s president and chief executive officer. “With more than 15 major companies now using PKS, we believe PKS has become the industry standard. Pharsight is committed to expanding PKS’s market penetration by continuing to work with pharmaceutical companies like Servier that recognize the importance of information technology to drive compliant, productive data management.”
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com .
About Servier
Servier is a privately-owned company, established in 1954 by its founder and current Chairman, Jacques Servier, M.D. Servier allocates approximately 25% of its turnover to Research and Development. Its main therapeutic products are used to treat diabetes, cardiovascular disease, neuropsychiatric disorders, cancer, and bone and joint diseases. In the past 18 months Servier has been able to file for registration three innovative pharmaceutical specialties in the field of osteoporosis, cardiovascular diseases and treatment of depression and two of them have already been accepted by EMEA.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the expanding market for Pharsight’s products, services and technology, trends in customer demand for Pharsight’s products, services and technology, the anticipated performance of Pharsight’s products, and the expected benefits to customers from the use of Pharsight’s products. Actual results may differ materially from Pharsight’s expectations due to a variety of factors, including: general market and business conditions; uncertainties in pharmaceutical drug development; changes in the demand for Pharsight’s products and services; changes in Pharsight’s research and development focus or operating strategies; the failure to develop new products and services or to keep pace with technological changes; delays in the release of new products and services; and the failure of products and services to obtain anticipated levels of customer acceptance or to meet customers’ expectations. Further information on potential factors that could affect actual results is included in Pharsight’s Quarterly Report on Form 10-Q, as filed with the Securities and Exchange Commission on November 14, 2005. All forward-looking statements are based on information available to Pharsight as of the date hereof, and Pharsight assumes no obligation to update such statements, whether as a result of new developments or otherwise.
Registered Trademarks and Trademarks
Pharsight, Pharsight Knowledgebase Server, PKS and WinNonlin are trademarks or registered trademarks of Pharsight Corporation. NONMEM(R) and SAS(R) are registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or JenniferBeugelmans, +1-415-896-6820, or media, Steve DiMattia, +1-646-277-8706, allof EVC Group for Pharsight
Web site: http://www.pharsight.com/
